Dependence on Sales of Certain Core Products
First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
29 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Because sales of certain major products account for a high proportion of sales in the Group's core pharmaceutical business, a decline in sales due to the launch and growth of competing products and generic drugs, as well as the discontinuation of sales or product recalls resulting from unexpected adverse reactions, product defects or disruptions to stable supply, may have a material impact on operating results and financial condition.」
The risks associated with dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, quality issues and supply disruptions are reaffirmed. - FY2025RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
The risks associated with dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, product defects and disruptions to stable supply are reaffirmed. - FY2022RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
The risks associated with dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, product defects and disruptions to stable supply are reaffirmed. - FY2021RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
The risks associated with dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, product defects and disruptions to stable supply are reaffirmed. - FY2020RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
Dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, product defects and disruptions to stable supply are reiterated. - FY2019RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
Dependence on sales of certain major products and the effects of competing products, generic drugs, adverse reactions, product defects and disruptions to stable supply are reiterated. - FY2018RestatedAnnual report
「Sales of certain major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
Dependence on sales of certain major products and the effects of competing products, generic drugs, product defects and disruptions to stable supply are reiterated. - FY2016First statedAnnual report
「Sales of Epadel and certain other major products account for a high proportion of sales in the pharmaceutical business, which is the core business of the Group.」
The principal channels of impact are discontinuation of sales and recalls caused by competing products and generic drugs, adverse reactions, product defects and disruptions to stable supply.